25 Jan 2012

TREND 1: Addressing Trial Complexity

by Lori Shields

Understanding clinical trial complexity will become more of a focus in 2012 as sponsors seek new ways to manage costs and speed study execution. It’s imperative to understand the impact that a more complex study design has on the success of the trial, particularly on the critical metrics of recruitment and retention of sites and subjects alike. We’ve seen significant growth in the complexity of study design globally, which requires more effort on the part of sites participating, but due to restrained budgets, sites are not always offered competitive reimbursement.

Our data on over 250,000 actual study grants around the world shows us a troubling trend in some US regions. Reimbursement rates for participating sites in the Northeast and Pacific regions have increased, but not enough to offset the high level of work and expertise required by increasing complex studies. Budget-focused sponsors have not appropriately factored in the amount of work that must be performed on a patient, how long it takes, the level of expertise required by the doctors or site staff, as well as the amount of data collected and the required data monitoring. If sites aren’t offered proper compensation for their efforts, sponsors are going to have a hard time recruiting them, putting study timelines at risk.

During study acceptance and the budget negotiation process, a site takes into account many factors and may make a decision to accept what might be considered a lower compensation for a particular study, especially if the drug or device shows promise to their patients. However, in a highly competitive situation, sites will be more apt to work with sponsors who take the complexity of the study design into account with respect to both reimbursement and timelines.

Complexity has a big impact on patient recruitment as well. With social media, patients have access to more and more information about studies available to them. A savvy patient might opt for a study that requires less of their time and fewer onerous procedures, such as blood work for the needle-phobe. I’ve even heard of sponsors getting patient input during the protocol review process—as a way to understand patient tolerance, eliminate unnecessary procedures, predict enrollment and potentially decrease dropout rates. I predict that this particular idea will spread farther in 2012 and I’m eager to see the resulting changes to complex study designs.

More about Lori Shields

Related posts

The Challenge of Extraneous Procedures in Study Design

Journalists in the trade and popular press seized on the ...

Getting the Pulse on the Industry: Soundbites from Medidata User Group

This year’s Americas Medidata User Group (AMUG) meeting was held ...

It Should Be All About the Patients

The end of June saw the start of summer and ...

TREND 3: System Integration to Streamline Trials

The integration of once disparate clinical trial systems will become ...

0

Comments in this post

  • There are no comments yet. You can be the first to leave a comment.

Leave a reply

274---274

Risk-Based Monitoring Updates: Tra ...

http://youtu.be/_dSiVnjNIyU A ri ...

How Life Sciences and Health Techno ...

http://youtu.be/VHiahhxHBeE Nina ...

Optimizing Clinical Trial Supplies

With the annual expenditures for cl ...

Talking Clinical Trials of the Futu ...

http://youtu.be/8h8o9igZmxA Nina ...

Product Management is Still a Game ...

As organizations have moved towards ...

Joe on Mobile Patient Data Capture — A Huge Step Forward
Nailed it.

john anstey on Ni Hao from Shanghai! 上海的你好
Great article. Exciting times ahead. I believe that China will award us the rare opportunity of applying our platform as...

Kajol on Data Management, Safety Systems and How Technology Can Improve Clinical Development Processes
It is a nice blog. It contain good information on clinical data management

Laurie Meehan on Providing Clarity on the Definitions of Source Data Verification (SDV) and Source Data Review (SDR)
Agreed - a new term would have been preferable, but we of course have the benefit of hindsight. We’re...

Steve Young on Providing Clarity on the Definitions of Source Data Verification (SDV) and Source Data Review (SDR)
Thanks Laurie for your thoughts. I agree with your concern regarding the "re-definition" of SDV by TransCelerate - particularly...